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ABSTRACT 
Introduction: Critically ill patients can experience 
stress-induced hyperglycaemia. Glycaemic con- 
trol therapy (GCT) is administered to control 
patients’ blood glycaemic levels and reduce the 
incidence of infection, myocardial infarctions 
and organ failure. However, there are many fac- 
tors influencing the effectiveness of glycaemic 
control for patients. This investigation aimed to 
review the method of Glycaemic Control Ther- 
apy (GCT) used in two hospital settings, to as- 
sess the effectiveness of glycaemic control on 
patients’ blood glycaemic levels and examine 
any barriers that may be in place. Method: A ret- 
nrospective audit was carried out on patients’ 
case notes in Intensive Care Units (ICU) within 
the East Midlands, UK. This method prevents the 
study outcomes being swayed because GCT has 
already taken place. To reduce selection bias the 
most recent available case notes were selected. 
All the patients who were admitted to these adult 
ICU’s between March and April 2010 had their 
case notes examined, those who were adminis- 
tered GCT were included in the study, this in- 
volved 79 from Hospital A and 50 from Hospital 
B. The patients’ notes were retrospectively au- 
dited. Results: Different glycaemic control pro- 
tocols were being implemented in each hospital, 
despite both belonging to the same ICU network. 
In most incidences, regardless of age, diabetes 
status or diagnosis, patients were administered 
the same sliding scale insulin (SSI). It was also 
found that GCT commenced for 41.9% (n = 52) of 
ICU patients (across both Hospitals) when gly- 
caemic levels were below the established thre- 
shold of 10 mmol/L. Additionally, a new glycae- 
mic range has been discovered, where 88.3% 
(n = 113) of patients (across both Hospitals) re- 
ceiving GCT were not controlled in hypogly- 
caemia, normoglycaemia or hyperglycaemia. They 
had mean blood glycaemic levels maintained 
between 5.6 - 9.9 mmol/L, now being described 
as medioglycaemia. Conclusions: The majority 
of patients receiving GCT were controlled in me- 
dioglycaemia and therefore a new comprehen- 
sive guideline needs to be developed incorpo- 
rating this new range. Recommendations also 
need to be established to adapt the titration 
regimen to individual patients, to improve the 
effectiveness and safety of glycaemic control. 
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1. INTRODUCTION 
Hyperglycaemia increases patients’ risk of myocardial 
infarction, cardiac failure and stroke, emphasising the 
need for effective Glycaemic Control Therapy (GCT) to 
be implemented [1].  
1.1. Stress-Induced Hyperglycaemia 
The endocrine cells in the pancreas normally maintain 
blood glycaemic levels between 3.9 - 5.5 mmol/litre. 
However, the body’s neuro-endocrine functions can be 
disrupted in critically ill patients causing blood glycae- 
mic levels to increase above normal ranges, known as 
stress-induced hyperglycaemia [1-3]. Stress-induced hy- 
perglycaemia can occur in critically ill patients who were 
previously not diabetic, but consequently may be suscep- 
tible to the same adverse health complications a person 
with diabetes mellitus experiences [4]. Controlling blood 
glycaemia reduces the incidence of severe infections, 
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sepsis, myocardial infarctions and multiple organ failure 
emphasising the need for effective glycaemic control 
[1,5-7].  
1.2. Landmark in the Development of Tight 
Glycaemic Control 
The introduction of Tight Glycaemic Control (TGC) 
by Van den Berghe et al.’s 2001 randomised controlled 
trial, challenged the then current belief that stress-in- 
duced hyperglycaemia was beneficial towards the pa- 
tients. When patients’ blood glycaemic levels were main- 
tained with conventional treatment between 180 - 200 
mg/dL (10 - 11.1 mmol/L) the patients mortality rate was 
8% (63 out of 783), compared to the TGC group main- 
taining glycaemic levels of 4.4 - 6.1 mmol/L (80 - 110 
mg/dL) where the mortality rate was 4.6% (35 out of 
765). Reduced organ failure and infection rates were also 
found [4]. In response to these findings, hundreds of 
ICU’s attempted to apply TGC to their practice [8]. 
1.3. Difficulties Found with the Tight  
Glycaemic Control Protocol 
It was discovered that many nurses found the TGC 
protocol complex to implement [9]. An audit found that 
only 32.8% (n = 11,916) of patient’s blood glycaemic 
levels were maintained within the TGC target range of 
4.4 - 6.1 mmol/L, compared to 81.9% (n = 29,739) of 
blood glycaemic values maintained in the Surviving 
Sepsis target range of <150 md/dL (8.3 mmol/L), illus- 
trating the problem of adherence to TGC. However, 
timely blood glycaemic measurements and accurate ad- 
justments could result in less variability and hypogly- 
caemic incidences [10,11]. 
1.4. Further Investigations 
A large randomised trial carried out by NICE-SUGAR 
investigators argued that TGC increases mortality rates 
and the number of second-degree hypoglycaemia (≤2.2 
mmol/L) events experienced [12]. Additionally, in 2006 
Van den Berghe et al.’s landmark study was repeated. 
This trial, however, failed to demonstrate the benefit of 
the intensive insulin therapy on mortality [13]. Further- 
more, the SepNet trial studied the use of TGC in patients 
with severe sepsis, but was stopped due to many hypo- 
glycaemic episodes [14]. Yet, the Surviving Sepsis Cam- 
paign still recommend that TGC is administered because 
the desirable effects of this implementation outweigh the 
unwelcome effects [15].  
1.5. Current Recommendations 
There are many conflicting recommendations in the  
literature for ICU practitioners to implement. There is no 
protocol in place that provides the ICU practitioners with 
guidelines that address the variety of patient diagnoses 
that affect glycaemic control [16,17]. This has empha- 
sised the need for further investigations in order to de- 
termine what is currently implemented and its effective- 
ness.  
2. METHOD 
2.1. Aims 
An Audit was used to examine what GCT is currently 
implemented in ICU settings and its impact on patient’s 
blood glycaemic levels.  
Null Hypothesis (H0): There would be no difference in 
the glycaemic control protocols used between the two 
hospitals. This was hypothesised because the hospitals 
belong to the same ICU network.  
2.2. Objectives 
 To review the method of glycaemic control used in 
both hospital settings. 
 To assess the effectiveness of glycaemic control on 
patients’ blood glycaemic levels. 
 To examine any barriers that may be in place affect- 
ing glycaemic control. 
2.3. Study Design 
Patients’ case notes were examined retrospectively, 
using a base line audit with self constructed standards.  
The patients’ case notes were examined and grouped 
into the type of GCT administered. Recorder blood gly- 
caemic levels were collected to determine 1) what level 
GCT commenced; 2) the efficiency of blood glycaemic 
control (by calculating the mean blood glycaemic level) 
to group into a) Hyperglycaemia (≥10 mmol/L) or b) be- 
low hyperglycaemia. Other information recorded in- 
cluded the patient demographics, time spent in ICU until 
GCT was commenced, overall length of stay and medi- 
cations such as the type of insulin and nutritional meth- 
ods administered. 
2.4. Sample 
The patients’ case notes that were admitted to each 
ICU over the two months: March and April of 2010, 
were examined. In “Hospital A” this was 169 case notes 
and in “Hospital B” this was 157 case notes. 
2.5. Data Collection 
The data were collected over a period of 12 weeks. 
The inclusion criteria were for all the patients to have 
been admitted to Adult ICU and to have had GCT whilst  
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in ICU between 1st March 2010 and 30th April 2010 (61 
days). Patients were excluded if they did not receive any 
GCT.  
2.6. Ethical Considerations 
Ethical approval is not required for a clinical audit, al- 
though, audit registrations were submitted to both hospi- 
tals and were approved by the Audit Clerks’ covering the 
Critical Care or diabetes directorate. Patient confidential- 
ity was maintained by making patients fully anonymous 
and examining their case notes in secure settings [18].  
2.7. Data Analysis 
The analytical statistics have been calculated in PASW 
Statistics 18. Cross tabulation Chi-square statistics were 
calculated to determine the significance of proportions of 
patients mean blood glycaemic levels being maintained 
in either hyperglycaemia (≥10 mmol/L) or below. Fisher’s 
Exact p value was then used to determine the exact 
probability of the outcomes in a 2 × 2 table because of 
small sample sizes.  
3. RESULTS 
3.1. Study Population 
The number of patients who fitted the inclusion crite- 
ria were 79 in Hospital A, 48 male:31 female, compared 
to 50 in Hospital B, 33 male:17 female. Both hospitals 
had the same age range of 16 - 87 years, but the mean 
age in Hospital A was 58 years compared to 63 years in 
Hospital B. 
The majority of patients receiving GCT in these hos- 
pital samples were non-diabetic, this included 75.9% (n 
= 60) of Hospital A’s patients and 60.0% (n = 30) in Hos- 
pital B. Type 1 Diabetic Mellitus patients’ made up 5.1% 
(n = 4) of patients in Hospital A and 12.0% (n = 6) in 
Hospital B, whilst Type 2 Diabetes Mellitus patients’ 
made up 19.0% (n = 15) of patients in Hospital A and 
28.0% (n = 14) in Hospital B.  
3.2. Glycaemic Control Therapy 
In Hospital A, 93.7% (n = 73) of patients were put on 
Actrapid intravenous SSI. A further 3.8% (n = 3) of pa- 
tients received an Actrapid bolus and the final 2.5% (n = 
2) of patients were on anti-diabetic tablets. The number 
of patients on GCT now equals 78 because of missing 
documentation for one Type 1 diabetic patient (excluded 
hereafter).  
In Hospital B, 92% (n = 46) of patients were put on 
Actrapid intravenous SSI. A further 6% (n = 3) of pa- 
tients were on Actrapid intravenous SSI converted to 
Actrapid subcutaneous SSI and 2% (n = 1) were on Ac-  
trapid subcutaneous SSI.  
3.3. Blood Glycaemic Control 
Table 1 shows the proportions of patients within 
each hospital controlled in hyperglycaemic ranges (≥10 
mmol/L) or below this. These two ranges have been 
chosen because the literature suggests that GCT com- 
mences when a patient becomes hyperglycaemic (10 
mmol/L) [12,16].   
The Fisher’s exact Chi-square test suggests a 77% 
probability (2-sided) that the proportional difference may 
be as a result of chance and therefore not statistically 
significant. However, the distribution of patients still 
indicates a trend that the majority of patients have GCT 
controlling their mean blood glycaemic levels below hy- 
perglycaemia. 
Examination of the data indicated that the two hospi- 
tals were controlling their patients below hyperglycaemia 
(≤9.9 mmol) but above normoglycaemia (≥5.6 mmol/L). 
Thus, the majority of patients who required GCT in ICU 
were being controlled in an uncategorised blood glycae- 
mic range (5.6 - 9.9 mmol/L). 
This uncategorised blood glycaemic range (5.6 - 9.9 
mmol/L) has not been previously published and therefore, 
will be referred to hereinafter as medioglycaemia [19].  
It was found that 88.3% (n = 113) of patients (across 
Hospital A and B) receiving GCT had mean blood gly- 
caemic levels maintained in the medioglycaemic range 
(5.6 - 9.9 mmol/L), see Table 2. None of the patients had 
mean blood glycaemic levels of ≤3.3 mmol/L (hypogly- 
caemic) [19].  
Figure 1 compares the patients mean blood glycaemic 
level with the glycaemic level when GCT was com-
menced on ICU in both hospitals. The horizontal line on 
the graph divides the patients into the groups of patients, 
who commenced GCT when the patient’s blood glycae- 
mic was 10 mmol/L.  
In Hospital A, 53.3% (n = 40) began GCT when the 
patient’s glycaemic levels were ≥10 mmol/L, whilst 
46.7% (n = 35) were commenced GCT when they were 
≤9.9 mmol/L. The two normoglycaemic patients and one 
other patient are not charted because the exact level GCT 
commenced was unknown. 
In Hospital B, 65.3% (n = 32) were commenced on 
GCT when their glycaemic levels were ≥10 mmol/L. 
However, 34.7% (n = 17) were still commenced on GCT 
when their blood glycaemic level was ≤9.9 mmol/L. One 
patient has also not been charted because the exact time 
their GCT commenced was not documented. 
Figure 2 displays the number of hours the patient was 
in ICU before GCT commenced. The hours were 
rounded up to the nearest whole hour. In Hospital A the 
number of hours ranged from 1 - 157 hours compared to  
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Table 1. Fisher’s exact test statistics examining the patients mean blood glycaemic level across both hospital sites. 
Mean Blood Glycaemic Levels 
Below Hyperglycaemia Hyperglycaemic 
9.9 mmol/L and below ≥10.0 mmol/L 
Fisher’s Exact Test 
 
Number (%) Number (%) Exact Significant 2 sided p value 
Hospital A 69 (88.5) 9 (11.5)  
Hospital B 46 (92.0) 4 (8)  
Total 115 (89.8) 13 (10.2) 0.765 
 
Table 2. Patients mean blood glycaemic level divided into the blood glycaemic ranges. 
Mean Blood Glycaemic Levels 
 Normoglycaemia Medioglycaemia *New Range* Hyperglycaemia 
 3.9 - 5.5 mmol/L 5.6 - 9.9 mmol/L ≥10 mmol/L 
 Number (%) Number (%) Number (%) 
Hospital A 2 (2.6) 67 (85.9) 9 (11.5) 
Hospital B 0 (0) 46 (92.0) 4 (8.0) 
Total 2 (1.6) 113 (88.3) 13 (10.1) 
 
 
Figure 1. Compares the patients mean blood glycaemic level with the glycaemic level 
when Glycaemic Control Therapy was commenced on Intensive Care Unit in both hos-
pitals. The horizontal line on the graph divides the patients into the groups of patients, 
who commenced Glycaemic Control Therapy when the patient’s blood glycaemic was 10 
mmol/L. 
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Figure 2. Examining the patient’s mean blood glycaemic level with their actual blood glycaemic level 
when Glycaemic Control Therapy was commenced and the number of hours the patient was on Intensive 
Care Unit before Glycaemic Control Therapy was initiated. 
 
1 - 114 in Hospital B. The majority of patients were 
commenced on GCT between 1 - 10 hours, including 
46.7% (n = 35) of patients in Hospital A compared to 
55.1% (n = 27) in Hospital B (Table 3).  
4. DISCUSSIONS 
Prior to the discussion of the results, a brief synopsis is 
provided of the protocols used in each of the respective 
hospitals because of the different glycaemic control pro- 
tocols implemented, despite both belonging to the same 
ICU network. In most incidences, regardless of age, dia- 
betes status or diagnosis, patients were administered the 
same SSI. 
4.1. Hospital Protocols  
Hospitals A and B have different Actrapid intravenous 
sliding scales with separate titrations, whilst Hospital B 
also administered a subcutaneous SSI infrequently, but 
on an irregular basis.  
Despite both hospitals belonging to the same ICU 
network, Hospital A had documented glycaemic control 
ranges of 1) 4 - 8.3 mmol/L; 2) 4 - 6.9 mmol/L and 3) 8 - 
11 mmol/L compared to 4 - 6.1 mmol/L in Hospital B.  
Additionally, Hospital B’s titration regimen was devel- 
oped in 2001, whilst Hospital A’s protocol and regimens 
were last updated in 2008.  
Thus, a number of issues have arisen, as a result of 
investigations in to these ITUs. 1) A variety of insulin 
protocols are available, which may or may not be im- 
plemented; 2) Insulin infusions are irregularly imple- 
mented, between and within these hospitals; 3) Proto- 
cols/regimens are out of date, which could impact the 
care provided.  
4.2. Discussion 
It was hypothesised that there would be no difference 
in the glycaemic control protocols used between the two 
hospitals but this audit has raised many questions sur- 
rounding the administration of GCT.  
Figure 1 illustrates the hyperglycaemic threshold of 
≥10 mmol/L [11] recommended by the NICE-SUGAR 
Investigators, [12] with a horizontal line. It shows that 
41.9% (n = 52) across Hospital A & B were commenced 
on GCT below this threshold of ≤10 mmol/L, despite the 
recommendations in the literature. On the other hand, the 
ADA recommends a threshold of 7.8 mmol/L for non- 
diabetic patients because they suggest this level is hyper- 
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Table 3. The majority of patients in both hospitals were commenced on Glycaemic Control Therapy between 1 - 10 hours with 
46.7% (n = 35) in Hospital A compared to 55.1% (n = 27) in Hospital B. 
 1 - 10 11 - 20 21 - 30 31 - 40 41 - 50 51 - 60 61 - 70 71 - 80 81 - 90 91 - 100 111 - 120 141 - 150 151 - 160 Total
Hospital A 35 9 9 8 3 3 2 1 0 2 1 1 1 75 
Hospital B 27 7 7 4 1 0 0 0 1 1 1 0 0 49 
Total 62 16 16 12 4 3 2 1 1 3 2 1 1 124
 
glycaemic for a non-diabetic [20]. While 8.3 mmol/L 
(150 mg/dL) is suggested to reduce the probability of 
sepsis, [15] yet there is little supporting evidence for 
this. As a result of this contradictory information, many 
healthcare practitioners are unsure as to which form of 
treatment is beneficial to the care and QoL for the pa- 
tient. 
This contradictory information could have resulted in 
many non-diabetics being commenced on insulin, when 
their glycaemic levels were within the medioglycaemic 
range. Both hospitals verbally stated, but had not previ- 
ously documented, that they commenced their insulin 
therapy at blood glycaemic values of ≥10 mmol/L (hy- 
perglycaemia), although, 41.9% (n = 52) were com- 
menced at values ≤ 9.9 mmol/L. The dichotomy between 
what is stated and actually delivered could indicate that 
hyperglycaemia levels may in fact be <10mmol/L, espe- 
cially as 71.4% (n = 90) of the patients in Hospital A and 
60.0% (n = 30) of the patients in Hospital B were 
non-diabetics requiring GCT. This may indicate that 
healthcare professionals are inappropriately and ineffec- 
tively diagnosing hyperglycaemia. 
Thus, the blood glycaemic level where GCT is com- 
menced needs to be re-evaluated.  
It has been found that patients who were commenced 
earlier on GCT were those who had had hyperglycaemic 
blood glycaemic values early on in their admission (Fig- 
ure 2). The patients who were commenced on GCT later 
than these patients seemed to have blood glycaemic lev- 
els that were medioglycaemic. It seems that in both hos- 
pitals, a decision was made to control their blood gly- 
caemic levels because they remained constantly above 
normal.  
The glycaemic control results have shown that there 
are now four glycaemic groups: 1) hypoglycaemia; 2) 
normoglycaemia; 3) medioglycaemia and 4) hypergly- 
caemia, with the introduction of this nascent mediogly- 
caemic range (5.6 - 9.9 mmol/L). What is important to 
establish, however, is the distinction between mediogly- 
caemia triggering GCT, and actually having blood glu- 
cose maintained in the medioglycaemic range.  
We shall now explore each of these points in turn: 
1) If medioglycaemia is the trigger for treatment, this 
means that clinicians perceive a need for treatment, but 
there is no empirical evidence for doing so; 
2) If blood glucose is being maintained within the me- 
dioglycaemic range, this reflects the wide variety of 
recommended maintenance values identified within the 
literature. However, there is a lack of consistency as to 
the ideal maintenance range. 
The American Association of Clinical Endocrinolo- 
gists (AACE) & American Diabetes Association (ADA) 
still fail to provide health professionals with a protocol 
that addresses the variety of patients admitted to ICU. An 
established glycaemic control protocol is, nevertheless, 
still required to accommodate the needs of patients ad- 
mitted with different diagnoses [17].  
Health professionals fear the implications of hyper- 
glycaemia and more so hypoglycaemia [13]. However, if 
patients are maintained within this medioglycaemic 
range with the development of a new TGC titration regi- 
men and protocol, healthcare professionals could reduce 
the glycaemic variance experienced by the patients and 
minimise still further the risks of hyperglycaemic and 
hypoglycaemic events [21].  
Defining normoglycaemia is also difficult. The nor- 
moglycaemic level used for this audit follows the ADA 
recommendations of between 3.9 - 5.5 mmol/L [22,23] 
although other published blood glycaemic ranges that are 
described as normoglycaemic include 4.4 - 6.1 mmol/L 
[13], 4.4 - 5.6 mmol/L [2] and 3.8 - 7.2 mmol/L [24]. This 
therefore, indicates inconsistencies surrounding the defi- 
nition of normoglycaemia and this will affect and deter- 
mine titration regimens.  
This audit confirms clinicians are maintaining gly- 
caemia within recommended ranges that together consti- 
tute medioglycaemia. However the ranges are wide and 
this is reflected in our data. Between one-third and one- 
half of all ICU patients on GCT have their treatment in- 
stigated below the established threshold of 10 mmol/L. 
Does this mean this level should be re-evaluated/ 
amended or are clinicians inadvertently responding to 
other cues about patients’ conditions, which are not re- 
corded in the audit data? 
Neither our data nor the literature can answer this 
question. Therefore, a qualitative study which addresses 
this question needs to be undertaken to try to establish 
why clinicians instigate GCT treatment below 10 mmol/ 
L. 
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4.3. Limitations 
Only selecting 2 months of data has meant that only a 
snap-shot of ICU glycaemic control data has been col-
lected and therefore cannot be generalised across the 
whole year, because the ICU environment is constantly 
changing with a variety of patients, diagnoses and rotat-
ing health professionals.  
Some patients’ notes were poorly documented, thus 
hindering the evaluation of what the patients may have 
been administered and how they were controlled.  
Mean blood glucose levels were calculated for each 
patient however, mean values can be distorted by ex-
treme values. Other metrics could have reflected differ-
ent blood glycaemic values [25]. 
5. CONCLUSIONS 
The retrospective audit carried out on patients’ case 
notes across two ICU’s in the East Midlands, UK has 
shown that different glycaemic control protocols were 
implemented in each intensive care setting, despite both 
belonging to the same ICU network. In most instances, 
regardless of age, diabetes status or diagnosis, patients 
were administered the same SSI, medications were not 
taken into account for protocol titrations and Actrapid 
was the only insulin used for SSI.  
The authors also established that the majority of pa-
tients receiving GCT were not controlled in hypogly-
caemia, normoglycaemia or hyperglycaemia, but within 
the nascent medioglycaemic range of 5.6 - 9.9 mmol/L. 
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LIST OF ABBREVIATIONS 
BG:    Blood Glucose 
DKA:   Diabetic Ketoacidosis  
DM:    Diabetes Mellitus 
Hyperglycaemia:  Glycaemic levels are ≥10mmol/L 
Hypoglycaemia:  Glycaemic levels are ≤3.3mmol/L 
ICU:    Intensive Care Unit 
Medioglycaemia:  Glycaemic levels between 5.6 - 9.9 
mmol/L 
TGC:   Tight Glycaemic Control 
T1DM:   Type 1 Diabetes Mellitus 
T2DM:   Type 2 Diabetes Mellitus 
IMPLICATIONS FOR CLINICAL  
PRACTICE 
The research has shown that different glycaemic con-
trol protocols were implemented in each intensive care 
setting, despite both belonging to the same ICU network.  
Patients were administered the same SSI, regardless of 
age, diabetes status or diagnosis. Patient medications 
were not taken into account for protocol titrations.  
Actrapid was the only insulin used for SSI despite the 
clear need for individualised care. The majority of pa-
tients receiving GCT were not controlled in hypogly-
caemia, normoglycaemia or hyperglycaemia, but within 
the posited medioglycaemic range of 5.6 - 9.9 mmol/L. 
FUTURE WORK 
More information needs to be gathered from other 
hospitals, so that the development of different titration 
regimens for specific diagnostic groups can advance. 
The glycaemic level that GCT should be commenced 
needs to be re-evaluated as there are inconsistencies 
surrounding the definition of normoglycaemia.  
The authors are now investigating glycaemic therapies 
and the ranges, therein. In addition, they are also inves-
tigating different insulin administrations because the 
audit found that the only insulin to be used for SSI 
within each ICU was Actrapid. 
 
 
 
